Tryton Medical has filed the final module of its pre-market approval (PMA) to US Food and Drug Administration (FDA) for its Side Branch Stent system.

The system was developed using Tri-ZONE technology to treat bifurcation lesions. Following approval from the FDA, the Side Branch Stent system is expected to become the first bifurcation stent in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

By using a standard single wire balloon expandable stent delivery system, the cobalt chromium stent will be deployed in the side branch artery, while a conventional drug eluting stent will be placed in the main vessel.

The PMA is supported by data from the single-arm Tryton confirmatory study, which showed an acceptable acute safety profile for the treatment of coronary bifurcation lesions in vessels appropriate for a =2.5mm stent.

"Tryton Medical’s differentiated technology addresses the unique challenges of bifurcated lesions, which affect nearly a third of all patients treated with angioplasty each year."

In addition, a post-hoc analysis from the Tryton randomised clinical trial showed the stent reduced target vessel failure and improved side branch percent diameter stenosis, when compared to provisional stenting in the intended treatment population.

Tryton Medical president Shawn McCarthy said: "Tryton Medical’s differentiated technology addresses the unique challenges of bifurcated lesions, which affect nearly a third of all patients treated with angioplasty each year.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"With today’s PMA filing we are one step closer to providing an important new option for interventional cardiologists in the US working to improve the quality of care for patients suffering from coronary artery disease."

The Side Branch Stent has been used to treat more than 11,000 patients worldwide and is marketed in multiple countries within Europe, Middle East and Africa.

The company noted the stent is investigational in the US and is not available in Japan.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact